COPD News

SAN DIEGO — Lung function decreased and COPD symptom burden increased among adults with vs. without food insecurity, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Using race-neutral equations to determine eligibility for COPD clinical trials may lead to higher percentages of Black patients enrolled, according to a poster presented at the American Thoracic Society International Conference.

SAN DIEGO — With dupilumab vs. placebo, adults with moderate to severe COPD and type 2 inflammation experienced fewer exacerbations, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — After 1 year of biologic therapy, patients with COPD and Th2 inflammation experienced fewer exacerbations and hospitalizations, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Among patients with moderate to severe COPD, 24-week ensifentrine improved dyspnea, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Bisoprolol treatment yielded a similar yearly rate of COPD exacerbations that require oral corticosteroids and/or antibiotics to placebo, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Patients with COPD treated with targeted lung denervation along with optimal COPD therapy experienced fewer exacerbations over 2 years, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Receiving treatment from a lung specialist for undiagnosed COPD or asthma lowered annual respiratory illness-related health care usage, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Patients with COPD on budesonide/glycopyrrolate/formoterol fumarate had a lower risk for cardiopulmonary outcomes, according to research presented at the American Thoracic Society International Conference.